PGK1 Antibody

1. PGK1 mutated variants display different catalytic activity and conformational stability compared to the native enzyme. PMID:29995887
2. The results indicate that ALDOA and PGK1 may indicate resistance to cisplatin in osteosarcoma PMID:29199648
3. PGK1 is used to indicate the prognosis of hepatocellular carcinoma (HCC). PMID:28749413
4. Data show that LINC00963 (MetaLnc9) interacted with the glycolytic kinase PGK1 and prevented its ubiquitination in non-small cell lung cancer (NSCLC) cells, leading to activation of the oncogenic AKT/mTOR signaling pathway. PMID:28923857
5. Acetylated PGK1 binds to and phosphorylates Beclin1 at S30, leading to activation of the VPS34-Beclin1 complex to initiate autophagosomal formation. PMID:28238651
6. Data suggest that, in breast cancer cells, MYC acts as an upstream regulator leading to PGK1 activation. (MYC, proto-oncogene c-myc; PGK1, phosphoglycerate kinase 1) PMID:28457968
7. PGK1, a glycolytic enzyme catalyzing the conversion of 3-phosphoglycerate into 2-phosphoglycerate, has increased expression in synovial tissues and blood of rheumatoid arthritis, which may be involved in pro-inflammation and synovial hyperplasia of the disease PMID:27342824
8. In neuroblastoma cells, CAIX and PGK1 expression is up regulated under hypoxia and correlates with response to targeted anti-proliferative treatment. PMID:26510737
9. Mitochindrial PGK1 acts as a protein kinase in coordinating glycolysis and the tricarboxylic acid cycle, which is instrumental in cancer metabolism and tumorigenesis. PMID:26942675
10. PI3K/AKT/mTOR pathway regulates HDAC3 S424 phosphorylation, which promotes HDAC3-PGK1 interaction and PGK1 K220 deacetylation PMID:26356530
11. Retinal dystrophy may be one of the clinical manifestations of phosphoglycerate kinase deficiency. PMID:26396085
12. mutations associated with hPGK1 deficiency lead to increased aggregation and proteolysis rates in vitro and inside cells due to protein thermodynamic destabilization PMID:24838780
13. Results show that PGK1 mRNA and protein expression were significantly increased in breast cancer tissues and can be considered as a prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer. PMID:25867275
14. Suppression of PGK1 enhanced the radiosensitivity of U251 xenografts and suggest that PGK1 may serve as a useful target in the treatment of radioresistant glioma. PMID:25175369
15. Phosphoglycerate kinase deficiency due to a novel mutation (c. 1180A>G) manifesting as chronic hemolytic anemia in a Japanese boy. PMID:24934115
16. PGK1 appears to play an important role for neuroblastoma PMID:24376734
17. different factors contributing to hPGK1 thermodynamic and kinetic stability PMID:24721582
18. PGK1 could promote radioresistance in U251 human cells. PMID:24284928
19. increased expression of PGK1 in colon cancer tissue is associated with metastasis. PMID:23727790
20. Generif: Phosphoglycerate kinase is a moonlighting protein that functions as both a glycolytic enzyme and a primer recognition protein of DNA polymerase alpha. PMID:2324090
21. Phosphoglycerate kinase is a moonlighting protein that functions as both a glycolytic enzyme and a disulfide reductase. PMID:11130727
22. Conformational dynamics in the catalytic cycle of phosphoglycerate kinase, molecular details provided by structural analysis. [Review] PMID:23684636
23. Glycolytic enzymes PGK1 and PKM2 are novel transcriptional targets of PPARgamma in breast cancer. PMID:23130662
24. the low kinetic stability displayed by PGK1 protein mutations is causing human PGK1 deficiency PMID:23336698
25. Phosphoglycerate kinase 1 was up-regulated significantly in radioresistant astrocytomas and also seems to be correlated with the negative prognosis following radiotherapy. PMID:22742733
26. carbonic anhydrase I, phosphoglycerate kinase 1 and apolipoprotein A-I appeared to be the most significant variations of proteins in patients with osteopenia and osteoarthritis PMID:22619369
27. two key (hub) PPARgamma direct target genes, PRKCZ and PGK1, were experimentally validated to be repressed upon PPARgamma activation by its natural ligand, 15d-PGJ2 in three prostrate cancer cell lines PMID:21780947
28. All findings indicate that the different clinical manifestations associated with PGK1 deficiency chiefly depend on the distinctive type of perturbations caused by mutations in the PGK1 gene PMID:22348148
29. enzyme kinetics studies show that the absence of the ribose OH-groups with is better tolerated for the purine than for the pyrimidine containing compounds in phosphoglycerate kinase 1 PMID:21505655
30. Molecular dynamics simulations were carried out with four different nucleotides (D-/L-ADP and D-/L-CDP) in complex with PGK and 1,3-bisphospho-d-glycerate. The binding affinities of CDPs were very weak while D- and L-ADP were better substrates. PMID:21549683
31. PGK domain movement and catalysis is regulated by a spring-loaded release mechanism PMID:21349853
32. Phosphoglycerate kinase 1 (PGK1) showed a difference between follicular cells from follicles leading to a pregnancy or developmental failure. PMID:19778949
33. PGK1-overexpressing fibroblasts with prostate tumor cells promoted tumor cell growth in vivo. Observations suggest that PGK1 helps support the interactions between cancer and its microenvironment. PMID:20068185
34. Data show that PGK1 regulates the expression of CXCR4 and beta-catenin at the mRNA and protein levels. PMID:19688824
35. Results suggest that conformational rearrangements in the hinge generated by binding of both substrates provide the main driving force for domain closure overcoming the slightly unfavourable contact interactions between the domains. PMID:19854185
36. Phosphorylates pyrimidine L-deoxynucleoside analog diphosphaates PMID:12080078
37. Overexpression induces a multidrug resistance phenotype. PMID:12174867
38. 3-phosphoglycerate kinase has a role in the activation of L-nucleoside analogs PMID:12869554
39. These results demonstrate that phosphpglycerate kinase regulates uPAR expression at the post-transcriptional level. PMID:14764427
40. production and secretion of PGK are regulated separately and oxygen and the protein hydroxylases can control not only gene expression but also protein secretion PMID:15053920
41. phosphoglycerate kinase does not appear to have a role in the development or progression of neoplasms [letter] PMID:15255553
42. During domain closure, Lys 215 in 3-phosphoglycerate kinase possibly moves together with the transferring phosphate, and this group is being positioned properly for catalysis. PMID:16363799
43. The impact of hypoxic treatment on the expression of PGK1 and the cytotoxicity of troxacitabine and gemcitabine are reported. PMID:17565005
44. our study indicates that inhibition of the transcription mechanism is the cause of PGK deficiency. PMID:17661373
45. Aa steady state kinetic and biophysical study of the interaction of the model compound l-MgADP with hPGK, is presented. PMID:18096512
46. Although L-ADP is almost as catalytically competent as D-ADP, under our experimental conditions (buffer containing 30% methanol, 4 degrees C) phosphoglycerate kinase binds D- and L-ADP with similar kinetics. PMID:18288812
47. overexpression of PGK1 and its signalling targets may be a expression-pathway in diffuse primary gastric carcinomas promoting peritoneal dissemination PMID:18453750
48. transmission path of the nucleotide effect toward the main hinge of phosphoglycerate kinase is described for the first time at the level of interactions existing in the tertiary structure[ 3-phosphoglycerate kinase] PMID:18540639
49. PGK1 was selectively overexpressed in human colon tumor cells by treating with hydrogen peroxide as oxidative stress, while its expression was suppressed by co-treatment with antioxidants. PMID:18603805

Show More

Hide All

HGNC: 8896

UNIGENE: Hs.78771

KEGG: hsa:5230

STRING: 9606.ENSP00000362413

OMIM: 300653